Equities

Inspecs Group PLC

Inspecs Group PLC

Actions
Consumer DiscretionaryPersonal Goods
  • Price (GBX)62.00
  • Today's Change4.00 / 6.90%
  • Shares traded1.12m
  • 1 Year change-50.60%
  • Beta2.6567
Data delayed at least 20 minutes, as of May 03 2024 14:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

INSPECS Group plc is a United Kingdom-based provider of eyewear solutions for the global eyewear market. The Company produces a range of eyewear frames, low vision aids and lenses, covering optical, sunglasses and safety, which are either under license or under the Company’s own proprietary brands (Branded), or unbranded or private label on behalf of retail customers (OEM). The Company’s segments include Frames and Optics, which is involved in product distribution; Wholesale, which is engaged in OEM and manufacturing distribution, and Lenses which is engaged in manufacturing and distribution of lenses. The Company has operations in the United Kingdom, Germany, Portugal, Scandinavia, the United States and China (including Hong Kong, Macau and Shenzhen). Its customers are global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 75,000 points of sale.

  • Revenue in GBP (TTM)203.29m
  • Net income in GBP-997.00k
  • Incorporated2019
  • Employees1.67k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Svas Biosana SpA101.23m4.39m38.34m374.008.380.72773.840.37880.95520.955222.0110.990.88123.002.94--3.822.825.904.8320.8427.164.333.781.374.840.2875--21.6611.3443.6021.78----
Bioretec Oy3.34m-3.24m44.56m37.00--6.08--13.33-0.1984-0.19840.20470.42130.55241.463.68105,594.60-53.58-67.11-65.75-97.6069.8570.97-96.98-134.054.86-4.020.0754--32.7719.77-56.82------
Visiomed Group SA10.31m-3.03m47.36m73.00--2.42--4.59-0.0119-0.01190.04060.07760.34531.406.88174,550.70-10.44-53.01-12.11-127.0991.4641.03-30.24-99.081.70-9.310.2631--101.386.67-18.40--52.36--
Affluent Medical SAS0.00-13.40m48.08m52.00---------0.5828-0.58280.00-----------------------------23.85---------2.80------
Novacyt SA7.87m-25.30m50.60m222.00--0.4715--6.43-0.4185-0.41990.13021.780.05281.330.262241,425.28-16.9617.69-20.7123.8243.2162.82-321.4023.874.98-79.020.00360.00-77.2813.49-269.46---13.46--
Paxman AB (publ)15.42m611.24k50.93m91.0083.77--25.763.300.43570.435711.03--------2,308,967.00---5.08---7.7669.6869.383.96-5.07--2.71----43.9929.35180.68------
Medicalgorithmics SA8.51m-113.95k52.91m122.00--2.89128.756.22-0.058-0.0584.339.300.35384.382.93---0.4736-0.9441-0.522-1.188.071.89-1.34-2.192.76--0.0579---31.28-26.39-102.27---18.81--
Senzime AB (publ)2.62m-9.84m54.47m52.00--2.35--20.76-1.49-1.490.38753.140.09461.315.60687,576.90-35.48-35.68-37.78-38.0023.32-20.59-375.20-558.686.97--0.0296--154.7761.90-1.09---3.69--
SDI Group PLC68.07m1.61m55.41m489.0034.911.279.390.8140.01520.01520.65280.41740.79582.086.29139,206.501.938.832.3411.4363.3464.572.4310.641.145.860.33110.0036.0936.05-48.6819.1111.86--
Inspecs Group PLC203.29m-997.00k58.97m1.67k--0.56974.900.2901-0.0109-0.01091.941.020.88642.248.68121,513.40-0.4347-1.48-0.6975-2.1550.9448.50-0.4904-1.970.86771.540.375--1.1636.4584.22--51.04--
Mentice AB20.08m-206.73k68.68m122.00--5.8937.463.42-0.1098-0.109810.906.220.83482.403.202,242,705.00-0.8595-7.69-1.69-13.0786.3983.67-1.03-10.001.01--0.0567--25.5411.7490.81---10.83--
OssDsign AB8.23m-9.58m69.66m----4.04--8.46-1.74-1.741.522.410.34086.546.19---39.65-38.80-44.90-44.7274.5872.29-116.35-203.054.15-30.390.0132--96.8253.26-31.30---60.35--
Optomed Oyj12.92m-3.80m71.84m114.00--4.04--5.56-0.2695-0.26950.92111.150.50021.674.92132,456.10-14.70-12.95-17.72-15.9067.8365.69-29.40-27.842.04-7.290.1926--3.003.4718.84--7.26--
Carmat SA2.39m-46.10m72.29m177.00------30.20-2.18-2.180.1128-1.090.04051.630.6353---77.90-76.92-97.48-94.38-1,109.12---1,925.92-4,636.641.19-17.091.88--710.72---0.3502--16.99--
Integrum AB7.06m606.03k75.48m34.00129.307.2499.2110.690.4470.4475.197.990.59180.58593.83--5.08-6.655.65-7.9586.8081.528.58-11.193.04-4.280.0462--33.2937.39-117.50--86.42--
Data as of May 03 2024. Currency figures normalised to Inspecs Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

57.18%Per cent of shares held by top holders
HolderShares% Held
Canaccord Genuity Wealth Ltd.as of 17 Apr 202418.82m18.52%
Downing LLPas of 19 Apr 20247.39m7.27%
Liontrust Investment Partners LLPas of 31 Dec 20225.69m5.60%
Amati Global Investors Ltd.as of 31 Dec 20225.69m5.60%
Hargreaves Lansdown Fund Managers Ltd.as of 31 Dec 20224.78m4.70%
Royal London Asset Management Ltd.as of 31 Dec 20223.97m3.90%
Invesco Asset Management Ltd.as of 31 Dec 20223.76m3.70%
Stonehage Fleming SAas of 31 Dec 20223.15m3.10%
Ninety One UK Ltd.as of 31 Dec 20232.58m2.54%
Threadneedle Asset Management Ltd.as of 31 Jan 20242.29m2.25%
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.